Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
ARIA began a dose-escalation, Italian and Swiss Phase Ib trial in about 55 patients for AP23573 in combination with capecitabine. AP23573 has Fast Track designation in the U.S. to treat soft tissue an...
